<code id='CE29C9CD5A'></code><style id='CE29C9CD5A'></style>
    • <acronym id='CE29C9CD5A'></acronym>
      <center id='CE29C9CD5A'><center id='CE29C9CD5A'><tfoot id='CE29C9CD5A'></tfoot></center><abbr id='CE29C9CD5A'><dir id='CE29C9CD5A'><tfoot id='CE29C9CD5A'></tfoot><noframes id='CE29C9CD5A'>

    • <optgroup id='CE29C9CD5A'><strike id='CE29C9CD5A'><sup id='CE29C9CD5A'></sup></strike><code id='CE29C9CD5A'></code></optgroup>
        1. <b id='CE29C9CD5A'><label id='CE29C9CD5A'><select id='CE29C9CD5A'><dt id='CE29C9CD5A'><span id='CE29C9CD5A'></span></dt></select></label></b><u id='CE29C9CD5A'></u>
          <i id='CE29C9CD5A'><strike id='CE29C9CD5A'><tt id='CE29C9CD5A'><pre id='CE29C9CD5A'></pre></tt></strike></i>

          entertainment

          entertainment

          author:Wikipedia    Page View:2
          a liver made up by geometric shapes – biotech coverage from STAT
          Adobe

          LONDON — A drug in development as a weight loss treatment succeeded in a Phase 2 study in a serious liver condition, its developers said Monday, as the competition in the broader obesity medicine field pushes ahead.

          The drug, survodutide, is being developed by the privately held German firm Boehringer Ingelheim and the Danish biotech Zealand Pharma. Zealand’s share price has doubled over the past year over the potential of the drug, and on Monday morning, shares jumped another 25%. 

          advertisement

          In the study, 83% of patients with a condition called MASH and who were treated with survodutide saw significant improvements in their disease compared to 18% of those who received placebo. The study met its primary endpoint of improvements in MASH after 48 weeks without the worsening of fibrosis, a scarring of the liver, the companies said. Secondary endpoints were also met, including an improvement in fibrosis. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more
          Elisabeth Bik tackles the widespread issue of research misconduct
          Elisabeth Bik tackles the widespread issue of research misconduct

          AlexHogan/STATElisabethBik,amicrobiologistbytraining,hasbecomeoneoftheworld’smostinfluentialscienced

          read more
          In age of alternative facts, a scholarly course on calling out crap
          In age of alternative facts, a scholarly course on calling out crap

          Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

          read more

          Doctor of U.S. President Joe Biden says he is fit for duty

          EvanVucci/APBETHESDA,Md.—PresidentJoeBiden “continuestobefitforduty,”hisdoctorwroteWednesdayaftercon